| edoxaban versus dalteparin | |||
| Hokusai-VTE Cancer, 2017 NCT02073682 | low-molecular-weight heparin for at least 5 days followed by oral edoxaban at a dose of 60 mg once daily. Treatment was given for atleast 6 months and up to 12 months. versus subcutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily for 1 month followed by dalteparin at a dose of 150 IU per kilogram once daily | patients with cancer who had acute symptomatic or incidental venous thromboembolism | open label |
| extended dalteparin versus standard treatment | |||
| CLOT (Lee), 2003 | Dalteparin 200 IU/kg daily for 1 month followed by 150 IU/kg daily for 5 months versus Dalteparin 200 IU/kg daily for 5-7 days followed by wafarin or acecumarol (target INR 2-3) for 6 months | patients with active cancer and with DVT or pulmonary embolism or both, and ECOG 1 or 2 | outcome assessment blinded Follow-up duration: 6 months |
| extended enoxaparin versus standard treatment | |||
| Cesarone, 2003 | Enoxaparin 100UL/Kg twice daily for 3 months versus coumadin (target INR 3) for 3 months. | patients with cancer with DVT | NA Follow-up duration: 3 months |
| Deitcher, 2006 | Enoxaparin 1mg/kg twice daily for 5 days followed by 1-1.5mg/kg daily for 175 days versus Enoxaparin 1mg/kg twice daily for 5 days followed by warfarin (target INR 2-3) for a total of 180 days | patients with cancer with DVT and/or PE | none Follow-up duration: 12 months |
| Meyer, 2002 | Enoxaparin 1.5 mg/kg daily for 3 monthsmag versus Enoxaparin 1.5 mg/kg daily for 4 days followed by warfarin (target INR 2-3) for 3 months | patients with cancer (solid or hematological; active or in remission but on treatment); with pulmonary embolism and/or DVT and a minimum life expectancy of 3 months | outcome assessment blinded Follow-up duration: 3 months |
| extended nadroparin versus standard treatment | |||
| Lopez Beret, 2001 | Nadroparin 1.025 antiXa IU/10Kg
twice daily after aadroparin 1.025AXa IU/10Kg twice daily for 3 days. After 3 months, nadroparin was switched to once daily versus acenocoumarol (target INR 2-3) for 3-6 months after nadroparin 1.025AXa IU/10Kg twice daily for 3 days | patients with known malignancy treated for symptomatic DVT of the lower limb | outcome assessment blinded Follow-up duration: 12 months |
| extended tinzaparin versus standard treatment | |||
| Hull, 2006 | Tinzaparin 175 antiXa/kg SQ daily for 12 weeks versus UFH for 5 days followed by vitamin K antagonist (target INR 2-3) for 12 weeks | patients with cancer (solid or hematological) with proximal DVT with or without PE and with a minimum life expectancy of 3 months imag | outcome assessment blinded Follow-up duration: 3 months |
| idraparinux versus standard treatment | |||
| Van Gogh (subgroup), 2011 | once-weekly subcutaneous injection of idraparinux (2.5 mg) for 6 months versus standard treatment for three months (8%) or six months (92%) | non-active and active cancer patients with deep venous thrombosis and without pulmonary embolism, included in the Van Gogh DVT clinical trial | Follow-up duration: 6 months |
| rivaroxaban versus dalteparin | |||
| SELECT D, 2018 | rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months) versus dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6) | patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lowerextremity proximal deep vein thrombosis (DVT) | open-design |
| rivaroxaban versus enoxaparin | |||
| EINSTEIN (subgroup), 2014 | rivaroxaban (15 mg twice daily for 21 days, followed by 20 mg once daily versus (enoxaparin1·0 mg/kg twice daily and warfarin or acenocoumarol; international normalised ratio 2·0–3·0 | subgroup analysis of patients with active cancer (either at baseline or diagnosed during the study) who were enrolled in the EINSTEIN-DVT and EINSTEIN-PE trials | |
| tinzaparin versus dalteparin | |||
| Wells (subgroup), 2005 | Tinzaparin 175 IU/kg SQ daily (warfarin started simultaneously and continued for 90 days) versus dalteparin 200 IU/kg daily for at least 5 days ((warfarin started simultaneously and continued for 90 days) | study subgroup of patients with cancer treated for upper or lower extremity DVT or PE in the outpatient setting | outcome assessment blinded Follow-up duration: 3 months |
| ximelagatran versus placebo | |||
| Schulman (subgroup), 2003 | extended treatment with Ximelagatran 24mg twice daily after initial anticoagulant treatment for 6 months versus placebo (initial anticoagulant treatment for 6 months) | study subgroup of patients with active cancer in the previous 5 years treated for DVT or pulmonary embolism for 6 months without recurrence | single blind and outcome ass. Follow-up duration: 18 months |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
